Citius Pharmaceuticals, Inc. (CTXR) P/E Ratio

Citius Pharmaceuticals, Inc. PE Ratio

The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.

• Citius Pharmaceuticals, Inc. pe ratio for the quarter ending 2024-06-30 was -133.06, a change of 22.74 year-over-year.
• Citius Pharmaceuticals, Inc. pe ratio for the quarter ending 2024-03-31 was -201.15, a change of -62.94 year-over-year.
• Citius Pharmaceuticals, Inc. pe ratio for the quarter ending 2023-12-31 was -152.57, a change of -49.48 year-over-year.
• Citius Pharmaceuticals, Inc. pe ratio for the quarter ending 2023-09-30 was -3.34, a change of 128.14 year-over-year.
• Citius Pharmaceuticals, Inc. pe ratio for fiscal 2024 was -133.06.
• Citius Pharmaceuticals, Inc. pe ratio for fiscal 2023 was -152.57, a change of -49.48 from fiscal 2022.
• Citius Pharmaceuticals, Inc. pe ratio for fiscal 2022 was -103.1, a change of 129.87 from fiscal 2021.
• Citius Pharmaceuticals, Inc. pe ratio for fiscal 2021 was -232.97, a change of -166.66 from fiscal 2020.